Advertisement
Product › Details
rozrolimupab (SYM001)
Next higher product group | polyclonal antibody | |
Status | 2005-08-23 development pp existent | |
Organisation | Symphogen A/S | |
Group | Servier (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for polyclonal antibody
- [1] Symphogen A/S. (4/3/20). "Press Release: Servier Signed a Definitive Agreement to Acquire Symphogen, a Leading Antibody Discovery Company, to Boost Its Antibody Capabilities and Leverage Its R&D Pipeline". Paris & Copenhagen....
- [2] Symphogen A/S. (5/15/19). "Press Release: Symphogen Announces New Capital Raise and Explores Strategic Options"....
- [3] Symphogen A/S. (9/3/18). "Press Release: Symphogen Elects New Board Members to Support the Company’s Long-term Development"....
- [4] Grifols S.A.. (7/5/17). "Press Release: Grifols Strengthens Its R&D+i through Investee Companies. Grifols Opens New Lines of Research with the Acquisition of a 44% Stake in GigaGen for USD 35 Million". Barcelona....
- [5] Abivax S.A.. (6/12/17). "Press Release: Abivax to Receive €390,000 from Bpifrance for the Development of Its Ebola Hyperimmune Candidate". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top